Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The agreement to acquire Dynavax is not expected to have any impact on Sanofi's financial guidance for 2025

  80% confidence

• This transaction and the compelling value it provides is in the best interests of the Company and its stockholders

  80% confidence

• The marketed adult hepatitis B vaccine and shingles candidate bring new options to Sanofi's portfolio and underscore commitment to providing vaccine protection across the lifespan

  80% confidence

• Joining Sanofi will provide the global scale and expertise needed to maximize the impact of Dynavax's vaccine portfolio

  80% confidence

• Shingles affects one in three adults over their lifetime

  80% confidence

• Sanofi's commercial reach, development capabilities, and commitment to evidence-based immunization will amplify the opportunity for HEPLISAV-B and innovative pipeline to address important public health needs

  80% confidence

• Dynavax enhances Sanofi's adult immunization presence by adding differentiated vaccines that complement Sanofi's expertise

  80% confidence

• Subject to satisfaction or waiver of customary closing conditions, the acquisition is expected to close in the first quarter of 2026

  80% confidence

Data points we hold from this source